Prolonged androgen deprivation leads to downregulation of androgen receptor and prostate-specific membrane antigen in prostate cancer cells

  • Authors:
    • Tiancheng Liu
    • Lisa Y. Wu
    • Melody D. Fulton
    • Jacqueline M. Johnson
    • Clifford E. Berkman
  • View Affiliations

  • Published online on: October 4, 2012     https://doi.org/10.3892/ijo.2012.1649
  • Pages: 2087-2092
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Emergence of androgen-independent cancer cells during androgen deprivation therapy presents a significant challenge to successful treatment outcomes in prostate cancer. Elucidating the role of androgen deprivation in the transition from an androgen-dependent to an androgen-independent state may enable the development of more effective therapeutic strategies against prostate cancer. Herein, we describe an in vitro model for assessing the effects of continuous androgen-deprivation on prostate cancer cells (LNCaP) with respect to the expression of two prostate-specific markers: the androgen receptor (AR) and prostate-specific membrane antigen (PSMA). Compared with androgen-containing normal growth medium, androgen-deprived medium apparently induced the concomitant downregulation of AR and PSMA over time. Decreased protein levels were confirmed by fluorescence imaging, western blotting and enzymatic activity studies. In contrast to the current understanding of AR and PSMA in prostate cancer progression, our data demonstrated that androgen-deprivation induced a decrease in AR and PSMA levels in androgen-sensitive LNCaP cells, which may be associated with the development of more aggressive disease-state following androgen deprivation therapy.

Introduction

Prostate cancer remains the second leading cause of cancer death for Northern American men. According to the National Cancer Institute, it is estimated that there will be 241,740 new cases and 28,170 deaths from prostate cancer in the United States in 2012 (http://www.cancer.gov/cancertopics/types/prostate). Initially, prostate cancer cells depend on androgen stimulation for growth and proliferation, and sensitive to androgen deprivation therapy. Unfortunately most recurrent tumors return within two years with an androgen-independent state and an aggressive, metastatic phenotype. As of yet there is no effective treatment for hormone-refractory prostate cancer (1,2).

Androgens and the androgen receptor (AR) are critical components that govern the development, differentiation, and functionality of the prostate gland and accessory reproductive tissues, and are also involved in prostate tumorigenesis (3). These pathological functions are dependent on the androgen-activated androgen receptor, which can act as a transcription factor to regulate the expression of multiple genes. Recently, several possible mechanisms (4,5) have been proposed for the progression of androgen-independent prostate cancer during androgen-deprivation therapy. Of them, mutation, amplification (5,6), and expression alternative-splice variants (7) of the androgen receptor are related to the adaptation of recurrent prostate cancer to low levels of androgen during androgen-deprivation therapy. Androgen deprivation also induces neuroendocrine differentiation (8) of prostate cancer cells leading to autocrine/paracrine signaling pathways for survival. In addition, androgen-independent prostate cancer cells have been characterized to exhibit stem cell-like properties (9,10).

Prostate-specific membrane antigen (PSMA), a type II membrane protein, has been found to be upregulated and strongly expressed on prostate tumor cells and as a consequence, it has attracted significant attention not only as a tumor marker for disease progression but also as both an imaging and therapeutic target for prostate cancer (11). Although previous studies revealed that PSMA expression was negatively regulated by androgen stimulation in AR-positive cells (1214) and downregulation of AR expression was mediated by androgen-deprivation in an established androgen-independent subline derived from the androgen-sensitive LNCaP cell line (4), there are no reports which investigate the expression of both AR and PSMA at the protein level after long-term androgen deprivation. Therefore, this study was designed to identify the effect of long-term androgen-deprived growth on these two prostate cancer markers with respect to possible implications on diagnostic and therapeutic strategies for the androgen-independent disease-state. First, androgen-sensitive LNCaP cells were cultured in androgen depleted media up to 20 passages. Second, the altered expression of PSMA and AR at the protein levels induced by androgen deprivation was determined by western blotting, fluorescence imaging analysis, and enzymatic activity. Our data suggest that long-term androgen deprivation may induce the concomitant time-dependent downregulation of both AR and PSMA to progress toward a more aggressive, androgen-independent prostate cancer disease state.

Materials and methods

Cell lines and reagents

The human prostate cancer cell lines LNCaP and PC-3 were obtained from the American Type Culture Collection (Manassas, VA, USA). The rabbit polyclonal anti-AR antibody (N-20) was obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). The goat anti-rabbit secondary antibody-FITC and the mouse monoclonal anti-GAPDH antibody (clone GAPDH-71.1) were obtained from Sigma-Aldrich (St. Louis, MO, USA). The mouse monoclonal anti-PSMA antibody 7E11 was graciously provided by Cytogen Corp. (Princeton, NJ, USA). Protein blocking solution was obtained from BioGenex (San Ramon, CA, USA). Hoechst 33342 was obtained from Invitrogen-Molecular Probes (Carlsbad, CA, USA). Cy5.5-CTT-54.2 was prepared by our lab as described previously (15). Halt Protease Inhibitor Cocktail (100X) was purchased from Thermo Fisher Scientific (Rockford, IL, USA). All other chemicals and cell-culture reagents were purchased from Fisher Scientific (Sommerville, NJ, USA) or Sigma-Aldrich.

Cell culture

LNCaP and PC-3 cells were grown in T-75 flasks with normal growth media [RPMI-1640 containing 10% heat-inactivated fetal calf serum (FBS), 100 U of penicillin and 100 μg/ml streptomycin] in a humidified incubator at 37°C with 5% CO2. Otherwise, for androgen-deprivation growth, cells were cultured with conditioned media [RPMI-1640 containing 10% charcoal-stripped fetal bovine serum, 100 U of penicillin and 100 μg/ml streptomycin]. Confluent cells were detached with a 0.25% trypsin 0.53 mM EDTA solution, harvested, and plated in two-well slide chambers at a density of 4×104 cells/well. Cells were grown for three days before conducting the following experiments.

Immunofluorescence detection of AR

The LNCaP cells, grown under androgen deprivation condition for over time (5, 10 and 20 passages), were cultured for 3 days on the slides in the conditioned media. For 2-day androgen-deprivation treatment, LNCaP cells were seeded on slides with normal growth media for 1-day growth, and replaced with conditioned media for another 2-day growth. Normal LNCaP cells and PC-3 cells were used for the AR-positive and AR-negative control respectively. These cells were seeded on slides with normal growth media for 3 days. Slides with 3-day growth cells in normal growth media or conditioned media were washed twice in PBS buffer (phosphate buffered saline), fixed in 4% paraformaldehyde in PBS buffer for 15 min at room temperature, and permeabilized with 0.2% Triton X-100 in PBS buffer for 5 min at room temperature. The permeabilized cells were blocked in block buffer (0.1% Tween-20, 5% goat normal serum in PBS buffer) for 2 h at room temperature and incubated with primary anti-AR antibody (100X diluted in block buffer) overnight at 4°C. After washing, the cells were incubated with a secondary antibody (goat anti-rabbit IgG-FITC, 40X diluted in 1% BSA, PBS buffer) for 2 h at room temperature, counterstained with Hoechst 33342, and mounted in Vectashield® Mounting Medium (Vector Laboratories, Inc., Burlingame, CA, USA) for confocal microscopy.

Affinity imaging of PSMAs with Cy5.5-CTT-54.2

The cells cultured on the 2-well slides were washed twice with warm medium (37°C) A (phosphate-free RPMI-1640 containing 1% FBS), then incubated with 1 ml of Cy5.5-CTT-54.2 (10 μM) in warm medium A for 1 h in a humidified incubator at 37°C and 5% CO2. The above treated cells were washed three times with cold-KRB buffer pH 7.4 (mmol/l: NaCl 154.0, KCl 5.0, CaCl2 2.0, MgCl2 1.0, HEPES 5.0, D-glucose 5.0) and fixed with 4% paraformaldehyde in KRB for 15 min at room temperature. The cellular nuclei were counterstained with Hoechst 33342, and then mounted in Vectashield Mounting Medium for microscopy.

Confocal laser scanning microscopy

Cells were visualized under 40× oil immersion objective using an LSM 510 META laser scanning microscope. Hoechst 33342 was excited with a Diode laser (405 nm), and the emission was collected with a BP420-480-nm filter. AR immunofluorescence (with goat anti-rabbit IgG-FITC) was excited at 488 nm using an Argon laser, and the emission was collected with a LP505-nm filter. PSMA-targeted imaging with Cy5.5-CTT-54.2 was excited using 633 nm from a HeNe laser, and the emission collected with an LP 650-nm filter. To reduce interchannel crosstalk, a multi-tracking technique was used, and images were taken at a resolution of 1,024×1,024 pixels. Confocal scanning parameters were set up so that the control cells without treatment did not have background fluorescence. The imaging colors of the fluorescent dyes, Hoechst 33342 and FITC, were defined as blue and green, respectively. As the emission wavelength of the near-infrared fluorescent dye Cy5.5 was beyond visible ranges, fluorescence pseudocolor of Cy5.5 was assigned as red. The images were edited by National Institutes of Health (NIH) Image J software (http://rsb.info.nih.gov/ij) and Adobe Photoshop CS2.

Whole cell lysate extraction and western blot analysis

The controls: PC-3 and LNCaP cells (cultured in normal growth media) and LNCaP cells under androgen deprivation over time (2 days, 5, 10 or 20 passages) were collected by scraping, washed once in ice-cold PBS, re-suspended in 3-fold cell pellet volumes of lysis buffer (1% NP-40, 20 mM Tris pH 8.0, 137 mM NaCl, 10% glycerol) (16,17) supplemented with 1X Halt Protease Inhibitor Cocktail for 15 min on ice, then transferred to Eppendorf tubes for centrifugation at 10,000 g for 15 min at 4°C, the supernatant was saved as whole-cell protein extracts. Protein concentrations were determined using Non-Interfering Protein Assay (G-Biosciences, St. Louis, MO, USA). Western blotting was performed as described previously with only minor modifications (17,18). In brief, detergent soluble proteins (30 μg) were loaded and separated on a NuPAGE™ 4–12% Bis-Tris Gel (Invitrogen, Carlsbad, CA, USA) by electrophoresis for 40 min at a constant 200 V under reducing conditions, and then transferred to a 0.45 μm PVDF Immobilon-P Transfer Membrane (Millipore Corp., Bedford, MA, USA) at 400 mA for 100 min in a transfer apparatus-Owl Bandit VEP-2 (Owl, Portsmouth, NH, USA) according to the manufacturer’s instructions. Membranes were incubated with primary antibody at corresponding dilution overnight at 4°C and then with horseradish peroxidase conjugated-second antibody for 1 h at room temperature. The immunoreactive bands were visualized using Protein Detector TMB Western Blot kit (KPL, Gaithersburg, MD, USA) following the manufacturer’s instructions.

Evaluation of PSMA relative enzymatic activity

HPLC-based PSMA enzymatic activity analysis was performed in triplicate as described previously with only minor modifications (19,20). Working solutions of the substrate (N-[4-(phenylazo)-benzoyl]-glutamyl-γ-glutamic acid, PABGgG) were made at 10 μM in Tris-buffer (50 mM, pH 7.4). Working solutions of each protein sample were diluted at 30 μg/ml in Tris-buffer (50 mM, pH 7.4 containing 1% Triton X-100). A typical incubation mixture (final volume 250 μl) was prepared by the addition of 200 μl Tris buffer (50 mM, pH 7.4) and PAB-Glu-γ-Glu (25 μl, 10 μM) in a test tube. The enzymatic reaction was initiated by the addition of 25 μl of the PSMA working solution. The reaction was allowed to proceed for 15 min with constant shaking at 37°C and terminated by the addition of 25 μl methanolic TFA (2.5% trifluoroacetic acid by volume in methanol) followed by vortexing. The quenched incubation mixture was quickly buffered by the addition of 25 μl K2HPO4 (0.1 M), vortexed, iced for 15 min, followed by centrifugation (10 min at 7,000 g). An 85-μl aliquot of the resulting supernatant was subsequently quantified for the contents of substrate and product by HPLC as previously described (21,22). Enzymatic activity for each protein sample was calculated from HPLC data. Activities were compared with normally-cultured LNCaP cells to evaluate relative enzymatic activity (REA).

Results

Downregulation of AR protein expression induced by androgen deprivation

In a positive control, a strong immunofluorescence signal for AR was observed throughout the nuclei of normal growth medium-cultured LNCaP cells (Fig. 1). In contrast, there is no signal for AR in AR-negative PC-3 cells (Fig. 1). Compared to the positive control, androgen deprivation induced downregulation of AR protein expression in LNCaP cells over time; AR was not detectable after 10 passages (Fig. 1). Based on these results, it is clear that downregulation of AR protein expression is a cell-adaptable response to prolonged androgen deprivation. Although the presented results were not consistent with the previous report which demonstrated that the administration of androgens resulted in downregulated AR mRNA levels in LNCaP cells (23), our data matched with androgen-independent LNCaP subline (4).

Affinity labeling of PSMA

Cy5.5-CTT-54.2, a specific PSMA fluorescent inhibitor (IC50 = 0.55 nM) was designed and evaluated for PSMA-targeted fluorescence imaging of LNCaP cells in our previous published study (15). In this study, Cy5.5-CTT-54.2 was employed to detect the change of active PSMAs on the cellular surface by fluorescence imaging of androgen-deprived LNCaP cells. Consistent with the results for AR immunofluorescence study above, the greatest cell labeling by Cy5.5-CTT-54.2 was observed for LNCaP cells cultured in normal growth media (Fig. 2A), with decreased signals through 5 passages under androgen-deprived conditions (Fig. 2B and C), and no detectable signals by 10 passages under the same conditions (Fig. 2D and E), similar to that of PSMA-negative PC-3 cells (Fig. 2F).

Western blot analysis

Western blot analysis further confirmed that the total amount of AR and PSMA decreased over time with a dramatic loss by 10 passages and absent after 20 passages in androgen-deprived conditions; GAPDH served as a protein loading controls (Fig. 3). These data suggest that downregulation of both AR and PSMA expression is dependent on the androgen levels and the length of time of androgen deprivation during cell growth.

PSMA relative enzymatic activity (REA)

Analysis of PSMA relative enzymatic activity revealed that there was an apparent increase for whole-cell protein samples for 2 days (REA = 1.26) and 5 passages (REA = 1.98), compared to the membrane-protein sample from normally-cultured LNCaP cells (Fig. 4). However, there was no detectable PSMA enzymatic activity after 10 passages in prolonged androgen-deprived conditions, similar to that of PSMA-negative PC-3 cells (Fig. 4), and consistent with the PSMA expression (Figs. 2 and 3).

Discussion

Our data suggest that long-term androgen-depletion may induce downregulation of AR and PSMA which may lead to a diagnostically and therapeutically elusive androgen-independent disease-state. These new data provide additional knowledge of androgen-independent prostate cancer progression compared to previous studies, which primarily focused on changes in AR ligand binding specificity that may result from gene structure changes (e.g., mutation, amplification, or spliced variant expression) or AR ligand-independent activation arising from alternative signal pathways that activate AR activity at the castration level of androgen (2,24). With respect to PSMA, it is thought that increased expression is correlated with prostate cancer progression, especially in recurrent, metastatic cancers after androgen deprivation therapy (25,26).

While increased or consistent AR levels have been reported in established androgen-independent LNCaP sublines (27,28), loss of AR expression has been detected in other LNCaP sublines (4). Although all androgen-independent LNCaP sublines have been derived from a parent androgen-sensitive LNCaP cell line, they have been established in different labs under various conditions such as passage number of starting parent LNCaP cells, culture conditions, and duration of propagation under androgen-deprived growth conditions, which may result in different characteristics. In addition, the parent androgen-sensitive LNCaP cell line is not a homogeneous population, but is a multiple hypotetraploid mixture including cells with 84, 86, 87 or more chromosomes (product description of CRL-1740, http://www.atcc.org/). Single or a combination of multiple factors may contribute to these contradictory observations on AR expression in these established LNCaP sublines. A recent microarray analysis on patient tissues revealed that strong AR expression was detected in benign prostate (83%), localized prostate cancer (100%), and lymph node metastasis (80%), but less (40%) in metastatic hormone-resistant prostate cancer (3). It was also noticed that two highly aggressive androgen-independent prostate cancer cell lines: DU145 and PC-3 are double-negative of AR and PSMA (29) and the loss of their AR and PSMA expression is due to epigenetic silencing by CpG island hypermethylation of their promoter regions (2931). The DU145 and PC-3 lines were derived from brain and bone metastases of prostate cancer, whereas the AR(+), PSMA(+) LNCaP cell line was derived from a lymph node metastasis. The attributes of these three cell lines are consistent with the above clinical analysis for AR expression. Although the molecular basis for downregulation of AR and PSMA expression still remains unclear, the present study reveals a dynamic progression in the loss of AR and PSMA expression during androgen deprivation. We also observed that LNCaP cells gained the capability of suspension growth and more rapid proliferation after 10 passages in culture with 10% charcoal-stripped fetal bovine serum and RPMI-1640 media (data not shown). Combined, the data suggest that the protein expression levels of AR and PSMA may correlate to the progression and metastatic sites of prostate cancer. Also, highly metastatic, aggressive, and androgen-independent prostate cancer cells are more likely to exhibit an AR(−) and PSMA(−) genotype. While some evidence is suggestive of novel roles for AR and PSMA as tumor-suppressor activity in androgen-independent prostate cancer cells (2,32), the loss of AR and PSMA expression may be a consequence of dedifferentiation or a stem cell-like transition of prostate cancer cells (33) induced by androgen deprivation.

It was observed that short-term androgen deprivation (up to 5 passages) lead to an apparent increase of PSMA enzymatic activity (Fig. 4) while cell labeling with a fluorescent PSMA inhibitor decreased for these time-points (Fig 2). This inconsistency may implicate a possible specific post-translational modification change (e.g., N-glycosylation pattern), which occurs during short-term androgen deprivation resulting in a modified PSMA with improved enzymatic activity and a relative loss of either affinity for inhibitors or cell-surface expression. In previous studies with cell lines and patient samples, different N-glycosylation patterns for PSMA have been detected (34,35). Furthermore, it has been confirmed that the different N-glycosylation patterns can strongly affect PSMA enzymatic activity (34,36). In addition, changes in substrate specificity and enzymatic activity were exhibited by brain GCP II (37,38), which shares sequence homology with PSMA (39), but is expressed in a different tissue.

In conclusion, our in vitro data suggest that the continuous, long-term androgen deprivation induces downregulation or loss of AR and PSMA expression in prostate cancer cells, which may have significance in the progression toward a more aggressive, metastatic prostate cancer disease-state during androgen deprivation therapy. The implication of these observations is that it may be critical to identify AR(+) or PSMA(+) tumors early to ensure the therapeutic efficacy of novel AR- or PSMA-targeted agents to treat recurrent, metastatic, and hormone-refractory prostate cancer patients. However, an unsolved question remains whether these androgen-independent LNCaP cells originate from the minor population of stem-like cancer cells or result from the accumulation of the changes in genetic structures, gene expression profiles, or alternative signal pathways in androgen-sensitive LNCaP cells.

Acknowledgements

The authors thank Cytogen Corp. (Princeton, NJ, USA) for the gift of the mouse monoclonal antibody 7E11, and extend their gratitude for technical assistance from C. Davitt and V. Lynch-Holm at the WSU Franceschi Microscopy and Imaging Center. This study was supported in part by the National Institutes of Health (R01CA140617).

References

1. 

H GustavssonK WelenJE DamberTransition of an androgen-dependent human prostate cancer cell line into an androgen-independent subline is associated with increased angiogenesisProstate62364373200510.1002/pros.2014515389782

2. 

Y NiuS AltuwaijriKP LaiAndrogen receptor is a tumor suppressor and proliferator in prostate cancerProc Natl Acad Sci USA1051218212187200810.1073/pnas.080470010518723679

3. 

JN DavisKJ WojnoS DaignaultElevated E2F1 inhibits transcription of the androgen receptor in metastatic hormone-resistant prostate cancerCancer Res661189711906200610.1158/0008-5472.CAN-06-249717178887

4. 

SO LeeSS DuttN NadimintyE PinderH LiaoAC GaoDevelopment of an androgen-deprivation induced and androgen suppressed human prostate cancer cell lineProstate6712931300200710.1002/pros.2062117626246

5. 

P SaraonK JarviEP DiamandisMolecular alterations during progression of prostate cancer to androgen independenceClin Chem5713661375201110.1373/clinchem.2011.16597721956922

6. 

HL DevlinM MudryjProgression of prostate cancer: multiple pathways to androgen independenceCancer Lett274177186200910.1016/j.canlet.2008.06.00718657355

7. 

PA WatsonYF ChenMD BalbasConstitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptorProc Natl Acad Sci USA1071675916765201010.1073/pnas.1012443107

8. 

TC YuanS VeeramaniFF LinAndrogen deprivation induces human prostate epithelial neuroendocrine differentiation of androgen-sensitive LNCaP cellsEndocr Relat Cancer13151167200610.1677/erc.1.01043

9. 

K ZhangDJ WaxmanPC3 prostate tumor-initiating cells with molecular profile FAM65Bhigh/MFI2low/LEF1low increase tumor angiogenesisMol Cancer9319201010.1186/1476-4598-9-31921190562

10. 

KM BaeZ SuC FryeExpression of pluripotent stem cell reprogramming factors by prostate tumor initiating cellsJ Urol18320452053201010.1016/j.juro.2009.12.09220303530

11. 

AK RajasekaranG AnilkumarJJ ChristiansenIs prostate-specific membrane antigen a multifunctional protein?Am J Physiol Cell Physiol288C975C981200510.1152/ajpcell.00506.200415840561

12. 

SJ LeeK LeeX YangNFATc1 with AP-3 site binding specificity mediates gene expression of prostate-specific-membrane-antigenJ Mol Biol330749760200310.1016/S0022-2836(03)00640-512850144

13. 

A GhoshWD HestonTumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancerJ Cell Biochem91528539200410.1002/jcb.10661

14. 

RS IsraeliCT PowellJG CorrWR FairWD HestonExpression of the prostate-specific membrane antigenCancer Res541807181119947511053

15. 

T LiuLY WuMR HopkinsJK ChoiCE BerkmanA targeted low molecular weight near-infrared fluorescent probe for prostate cancerBioorg Med Chem Lett2071247126201010.1016/j.bmcl.2010.09.05720947349

16. 

JY MatrouleCM CarthyDJ GranvilleO JoloisDW HuntJ PietteMechanism of colon cancer cell apoptosis mediated by pyropheophorbide-a methylester photosensitizationOncogene2040704084200110.1038/sj.onc.120454611494135

17. 

T LiuLY WuCE BerkmanProstate-specific membrane antigen-targeted photodynamic therapy induces rapid cytoskeletal disruptionCancer Lett296106112201010.1016/j.canlet.2010.04.00320452720

18. 

T LiuY ToriyabeCE BerkmanPurification of prostate-specific membrane antigen using conformational epitope-specific antibody-affinity chromatographyProtein Expr Purif49251255200610.1016/j.pep.2006.05.008

19. 

T LiuLY WuM KazakCE BerkmanCell-surface labeling and internalization by a fluorescent inhibitor of prostate-specific membrane antigenProstate68955964200810.1002/pros.2075318361407

20. 

LY WuMO AndersonY ToriyabeThe molecular pruning of a phosphoramidate peptidomimetic inhibitor of prostate-specific membrane antigenBioorg Med Chem1574347443200710.1016/j.bmc.2007.07.02817869524

21. 

MO AndersonLY WuNM SantiagoSubstrate specificity of prostate-specific membrane antigenBioorg Med Chem1566786686200710.1016/j.bmc.2007.08.00617764959

22. 

J MaungJP MallariTA GirtsmanProbing for a hydrophobic a binding register in prostate-specific membrane antigen with phenylalkylphosphonamidatesBioorg Med Chem1249694979200410.1016/j.bmc.2004.06.031

23. 

DA WolfT HerzingerH HermekingD BlaschkeW HorzTranscriptional and posttranscriptional regulation of human androgen receptor expression by androgenMol Endocrinol792493619938413317

24. 

Y NiuTM ChangS YehWL MaYZ WangC ChangDifferential androgen receptor signals in different cells explain why androgen-deprivation therapy of prostate cancer failsOncogene2935933604201010.1038/onc.2010.12120440270

25. 

JS RossCE SheehanHA FisherCorrelation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancerClin Cancer Res963576362200314695135

26. 

S PernerMD HoferR KimProstate-specific membrane antigen expression as a predictor of prostate cancer progressionHum Pathol38696701200710.1016/j.humpath.2006.11.01217320151

27. 

JM KokontisN HayS LiaoProgression of LNCaP prostate tumor cells during androgen deprivation: hormone-independent growth, repression of proliferation by androgen, and role for p27Kip1 in androgen-induced cell cycle arrestMol Endocrinol12941953199810.1210/mend.12.7.01369658399

28. 

N IshikuraH KawataA NishimotoR NakamuraN IshiiY AokiEstablishment and characterization of an androgen receptor-dependent, androgen-independent human prostate cancer cell line, LNCaP-CS10Prostate70457466201019902465

29. 

H SuzukiT UedaT IchikawaH ItoAndrogen receptor involvement in the progression of prostate cancerEndocr Relat Cancer10209216200310.1677/erc.0.010020912790784

30. 

A ChlenskiK NakashiroKV KetelsGI KorovaitsevaR OyasuAndrogen receptor expression in androgen-independent prostate cancer cell linesProstate476675200110.1002/pros.104811304731

31. 

P Mhawech-FaucegliaDJ SmiragliaW BsharaProstate-specific membrane antigen expression is a potential prognostic marker in endometrial adenocarcinomaCancer Epidemiol Biomarkers Prev17571577200810.1158/1055-9965.EPI-07-0511

32. 

A GhoshX WangE KleinWD HestonNovel role of prostate-specific membrane antigen in suppressing prostate cancer invasivenessCancer Res65727731200515705868

33. 

Y TangAW HamburgerL WangMA KhanA HussainAndrogen deprivation and stem cell markers in prostate cancersInt J Clin Exp Pathol3128138200920126580

34. 

A GhoshWD HestonEffect of carbohydrate moieties on the folate hydrolysis activity of the prostate specific membrane antigenProstate57140151200310.1002/pros.1028912949938

35. 

EH HolmesTG GreeneWT TinoAnalysis of glycosylation of prostate-specific membrane antigen derived from LNCaP cells, prostatic carcinoma tumors, and serum from prostate cancer patientsProstateSuppl72529199610.1002/(SICI)1097-0045(1996)7+%3C25::AID-PROS3%3E3.0.CO;2-I

36. 

C BarinkaP SachaJ SklenarIdentification of the N-glycosylation sites on glutamate carboxypeptidase II necessary for proteolytic activityProtein Sci1316271635200410.1110/ps.0462210415152093

37. 

R Luthi-CarterAK BarczakH SpenoJT CoyleHydrolysis of the neuropeptide N-acetylaspartylglutamate (NAAG) by cloned human glutamate carboxypeptidase IIBrain Res795341348199810.1016/S0006-8993(98)00244-39622670

38. 

CW TiffanyRG LapidusA MerionDC CalvinBS SlusherCharacterization of the enzymatic activity of PSM: comparison with brain NAALADaseProstate392835199910.1002/(SICI)1097-0045(19990401)39:1%3C28::AID-PROS5%3E3.0.CO;2-A10221263

39. 

R Luthi-CarterAK BarczakH SpenoJT CoyleMolecular characterization of human brain N-acetylated alpha-linked acidic dipeptidase (NAALADase)J Pharmacol Exp Ther286102010251998

Related Articles

Journal Cover

December 2012
Volume 41 Issue 6

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Liu, T., Wu, L.Y., Fulton, M.D., Johnson, J.M., & Berkman, C.E. (2012). Prolonged androgen deprivation leads to downregulation of androgen receptor and prostate-specific membrane antigen in prostate cancer cells. International Journal of Oncology, 41, 2087-2092. https://doi.org/10.3892/ijo.2012.1649
MLA
Liu, T., Wu, L. Y., Fulton, M. D., Johnson, J. M., Berkman, C. E."Prolonged androgen deprivation leads to downregulation of androgen receptor and prostate-specific membrane antigen in prostate cancer cells". International Journal of Oncology 41.6 (2012): 2087-2092.
Chicago
Liu, T., Wu, L. Y., Fulton, M. D., Johnson, J. M., Berkman, C. E."Prolonged androgen deprivation leads to downregulation of androgen receptor and prostate-specific membrane antigen in prostate cancer cells". International Journal of Oncology 41, no. 6 (2012): 2087-2092. https://doi.org/10.3892/ijo.2012.1649